News

CT-0525 is an ex vivo gene-modified autologous CAR-monocyte cellular therapy being evaluated for the treatment of HER2-overexpressing solid tumors.

Mrinal M. Gounder, MD, delves into the data supporting the recent FDA approval of nirogacestat for the treatment of adult patients with desmoid tumors.

In the phase 3 MURANO trial, there was a continued survival benefit in patients with chronic lymphocytic leukemia treated with fixed-duration venetoclax plus rituximab.

The potential of CTLA4 deletion as a strategy to improve chimeric antigen receptor T-cell efficacy was observed in a study published in Immunity.

A fast track designation has been granted to zotatifin with fulvestrant, and abemaciclib for adult patients with estrogen receptor-positive/HER2-negative advanced or metastatic breast cancer.

Olvimulogene nanivacirepvec, an oncolytic viral-based therapy, has earned a fast track designation from the FDA in ovarian cancer resistant or refractory to platinum-based chemotherapy.

Nirogacestat is now an FDA-approved option for adult patients with progressing desmoid tumors who require systemic treatment.

The phase 3 DREAMM-7 trial met its primary end point of progression-free survival, and overall survival data is trending positively.

The biologics license application seeking the approval of obe-cel as a potential therapeutic option in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia has been submitted to the FDA.

Liza C. Villaruz, MD, discusses what research in the EGFR-positive lung cancer space has recently caught the attention of experts.

In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.

The FDA breakthrough drug designation for epcoritamab in follicular lymphoma was supported by findings from the phase 1/2 EPCORE NHL-1 study.

An investigational new drug application for TCB008 has been cleared by the FDA. A phase 1B trial will now assess the agent in patients with relapsed/refractory acute myeloid leukemia.

Among patients with chronic lymphocytic leukemia who progressed after treatment, pirtobrutinib demonstrated a clearance of BTK C481 clones and the development of non-C481 clones.

Steady-state and chemotherapy-based mobilization both demonstrate feasibility in stem cell collection for patients with multiple myeloma undergoing autologous stem cell transplants, but challenges remain.

Mohamad Adham Salkeni, MD, FRCPC, discusses the mechanism of action of ivaltinostat and what rationalizes its use in combination with capecitabine for patients with metastatic pancreatic adenocarcinoma.

In an interview with Targeted Oncology, Jeff Stein, PhD, discussed the challenges and prospects of CD73-targeting agents.

In an interview with Targeted Oncology, Chris Haqq, MD, PhD, discussed the potential use of cancer vaccines in patients with KRAS-mutated pancreatic and colon cancer.

Domenech Asbun, MD, discusses first-, second-, and later lines of therapy for patients with gastrointestinal stromal tumor.

Neal Shore, MD, FACS, discussed the phase 3 EMBARK trial and what the FDA approval of enzalutamide means for the prostate cancer treatment landscape.

In addition to the approval of capivasertib and fulvestrant, the FDA has granted approval to the FoundationOne® CDx as a companion diagnostic to identify patients with advanced HR-positive, HER2-negative advanced breast cancer.

The rate of undetectable minimal residual disease at 10-4 in bone marrow was 77%, including a 71% rate among 14 patients with chronic lymphocytic leukemia refractory to prior Bruton tyrosine kinase inhibitors treated with venetoclax, umbralisib, and ublituximab.

VBI-1901 10µg plus GM-CSF had a disease control rate of 44% among 16 patients with recurrent glioblastoma in a phase 1/2a study.

Findings from the EPCORE CLL-1 trial were presented by Arnon Kater, MD, PhD, during the 2023 International Workshop on CLL, held October 6 to 9, 2023, in Boston, Massachusetts.

Nasir Chaudry, MD, discusses the significant advancements in the prostate cancer space in recent years.

AMG 193 had a promising safety profile and robust target engagement in a dose-escalating trial across tumor types.

Results from a phase 1/2a trial showed that plixorafenib had potential regarding safety and efficacy in BRAF-mutated solid tumors, especially in primary central nervous system tumors.

Along with improvements shown for the primary and secondary end points of the phase 3 MANIFEST-2 trial in JAK inhibitor-naive patients with myelofibrosis, pelabresib plus ruxolitinib did not display any new safety signals.

The combination of olaptesed pegol, bevacizumab, and radiotherapy showed an improvement in overall survival among patients with glioblastoma, according to findings from a phase 1/2 study.